Vivoryon Therapeutics N.V. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was EUR 10.76 million. Net income was EUR 4.41 million compared to net loss of EUR 4.63 million a year ago. Basic earnings per share from continuing operations was EUR 0.22 compared to basic loss per share from continuing operations of EUR 0.23 a year ago. Diluted earnings per share from continuing operations was EUR 0.22.
For the nine months, sales was EUR 10.76 million. Net loss was EUR 7.26 million compared to EUR 12.21 million a year ago. Basic loss per share from continuing operations was EUR 0.36 compared to EUR 0.61 a year ago.